- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SNMMI: PSMA-18F DCFPyL Changes Treatment for PCa Recurrence in Significant Number of Patients with Low PSAs
In a cohort of 85 patients with biomechanical recurrence of prostate cancer and PSA values less than 2 ng/mL, positive findings on PET imaging with PSMA-18F DCFPyL led to treatment changes in the majority of patients who had negative findings on conventional imaging, according to new research presented at the SNMMI conference.
The use of PSMA-18F DCFPyL may be more advantageous than conventional imaging in detecting biomechanical recurrence of prostate cancer in patients with low prostate-specific antigen (PSA) values, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
For the retrospective study, researchers evaluated the use of PET PSMA-18F DCFPyL (Pylarify, Lantheus) in 85 patients (mean age of 69) who had occult prostate cancer recurrence and PSA values less than 2 ng/mL. All patients in the cohort had negative computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET)-choline exams, according to the study authors.
At a six-month follow-up, the researchers found that PET imaging with PSMA-18F DCFPyL led to treatment changes in 75 percent of patients with positive findings (31/41).
Here one can see PET/CT imaging with PSMA-18F DCFPyL that led to modification with a planned radiotherapy treatment for recurrent prostate cancer. (Images courtesy of SNMMI.)
“In PET-PSMA-positive patients, the therapeutic changes found were classified as indicating or changing the planning of salvage radiotherapy treatment and/or initiating systemic treatment with hormone therapy,” noted lead study author Pedro Jose Plana Lopez, M.D., who is affiliated with Hospital Del Mar in Barcelona, Spain, and colleagues.
The study authors noted a median PSA level of 0.08 ng/dL after treatment changes were instituted in patients with positive PET PSMA results.
(Editor’s note: For related content, see “Can an Emerging PET Radiotracer Be a Viable Alternative to Multiparametric MRI for Detecting Prostate Cancer Recurrence?,” “Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence” and “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer.”)
“PET-PSMA is a powerful diagnostic tool for patients with occult biochemical recurrence with PSA < 2ng/mL,” added Lopez and colleagues.
Reference
1. Lopez PJP, Amorelli FG, Cano JSB, et al. PET/CT PSMA-18F DCFPyL promotes treatment changes in occult biochemical recurrence of prostate carcinoma even with low PSA values. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 9, 2024.
Radiology ‘Game-Changer’: FDA Approves PET Agent for Enhanced Detection of Coronary Artery Disease
September 28th 2024Offering higher diagnostic efficacy than SPECT imaging for coronary artery disease (CAD) detection, the PET myocardial perfusion imaging agent Flyrcado™ (flurpiridaz F 18, GE HealthCare) provides unit dose availability and effectiveness in imaging patients with high BMI.
Study Shows MRI-Targeted Biopsies Reduce Overdiagnosis of Clinically Insignificant PCa by 57 Percent
September 27th 2024Omitting biopsy procedures in men with PSA levels > 3 ng/ml and negative MRI findings for prostate cancer (PCa) was associated with significantly lower risks of diagnosing clinically insignificant PCa in comparison to the use of systematic biopsy, according to an approximately four-year study of over 13,000 men who had prostate cancer screening.
PSMA PET/CT or mpMRI: Which is Better for Diagnosing Biochemical Recurrence of PCa?
September 24th 2024A new meta-analysis found that PSMA PET/CT offers a 12 percent higher positivity rate for detecting biochemical recurrence of PCa and a 19 percent higher positivity rate for identifying lymph node metastasis in comparison to mpMRI.
